Onesource Specialty Pharma DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025


0.08×	0.80×	0.27×
−0.19×	−3.66×	−0.35×
6.4%	1.8%	13.3%
0.18×	0.18×	0.19×
1.45×	1.41×	1.28×
−0.0%	−1.3%	−0.3%
−1.3%	−1.3%	−0.3%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ONESOURCE₹1,569.60

Onesource Specialty Pharma Ltd.

· Pharma & Health

₹ CrorePeersSTAR DIVISLAB GLAND PFIZER POLYMED RAINBOW KIMS JUBLPHARMAMcap ₹17,991 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.27	0.80	0.08
Interest Burden (Pretax/EBIT) ×	-0.35	-3.66	-0.19
EBIT Margin %	13.33	1.77	6.39
Asset Turnover ×	0.19	0.18	0.18
Financial Leverage (Assets/Equity) ×	1.28	1.41	1.45
ROE (5-step product, year-end total equity) %	-0.30	-1.32	-0.03
ROE (owners' profit / average owners' equity) %	-0.31	-1.26	-1.26

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.